Literature DB >> 23958599

From NAFLD to NASH to cirrhosis-new insights into disease mechanisms.

Alexander Wree1, Lori Broderick, Ali Canbay, Hal M Hoffman, Ariel E Feldstein.   

Abstract

NAFLD has evolved as a serious public health problem in the USA and around the world. In fact, NASH-the most serious form of NAFLD-is predicted to become the leading cause of liver transplantation in the USA by the year 2020. The pathogenesis of NAFLD and NASH, in particular the mechanisms responsible for liver injury and fibrosis, is the result of a complex interplay between host and environmental factors, and is at the centre of intense investigation. In this Review, we focus on recently uncovered aspects of the genetic, biochemical, immunological and molecular events that are responsible for the development and progression of this highly prevalent and potentially serious disease. These studies bring new insight into this complex disorder and have led to the development of novel therapeutic and diagnostic strategies that might enable a personalized approach in the management of this disease.

Entities:  

Mesh:

Year:  2013        PMID: 23958599     DOI: 10.1038/nrgastro.2013.149

Source DB:  PubMed          Journal:  Nat Rev Gastroenterol Hepatol        ISSN: 1759-5045            Impact factor:   46.802


  116 in total

1.  Microbiota: Dysbiosis driven by inflammasome deficiency exacerbates hepatic steatosis and governs rate of NAFLD progression.

Authors:  Natalie J Wood
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2012-02-21       Impact factor: 46.802

2.  Metabolic profiling reveals a contribution of gut microbiota to fatty liver phenotype in insulin-resistant mice.

Authors:  Marc-Emmanuel Dumas; Richard H Barton; Ayo Toye; Olivier Cloarec; Christine Blancher; Alice Rothwell; Jane Fearnside; Roger Tatoud; Véronique Blanc; John C Lindon; Steve C Mitchell; Elaine Holmes; Mark I McCarthy; James Scott; Dominique Gauguier; Jeremy K Nicholson
Journal:  Proc Natl Acad Sci U S A       Date:  2006-08-08       Impact factor: 11.205

3.  Absence of invariant natural killer T cells deteriorates liver inflammation and fibrosis in mice fed high-fat diet.

Authors:  Takuya Miyagi; Tetsuo Takehara; Akio Uemura; Kumiko Nishio; Satoshi Shimizu; Takahiro Kodama; Hayato Hikita; Wei Li; Akira Sasakawa; Tomohide Tatsumi; Kazuyoshi Ohkawa; Tatsuya Kanto; Naoki Hiramatsu; Norio Hayashi
Journal:  J Gastroenterol       Date:  2010-07-02       Impact factor: 7.527

Review 4.  Inflammasomes in liver diseases.

Authors:  Gyongyi Szabo; Timea Csak
Journal:  J Hepatol       Date:  2012-05-23       Impact factor: 25.083

Review 5.  Metabolic effects of fructose and the worldwide increase in obesity.

Authors:  Luc Tappy; Kim-Anne Lê
Journal:  Physiol Rev       Date:  2010-01       Impact factor: 37.312

6.  Fas enhances fibrogenesis in the bile duct ligated mouse: a link between apoptosis and fibrosis.

Authors:  Ali Canbay; Hajime Higuchi; Steven F Bronk; Makiko Taniai; Tom J Sebo; Gregory J Gores
Journal:  Gastroenterology       Date:  2002-10       Impact factor: 22.682

Review 7.  Omega-3 PUFA derived anti-inflammatory lipid mediator resolvin E1.

Authors:  Hiroyuki Seki; Yukako Tani; Makoto Arita
Journal:  Prostaglandins Other Lipid Mediat       Date:  2009-03-25       Impact factor: 3.072

8.  The lysosomal-mitochondrial axis in free fatty acid-induced hepatic lipotoxicity.

Authors:  ZhengZheng Li; Michael Berk; Thomas M McIntyre; Gregory J Gores; Ariel E Feldstein
Journal:  Hepatology       Date:  2008-05       Impact factor: 17.425

Review 9.  Does fructose consumption contribute to non-alcoholic fatty liver disease?

Authors:  Luc Tappy; Kim-Anne Lê
Journal:  Clin Res Hepatol Gastroenterol       Date:  2012-07-12       Impact factor: 2.947

10.  Kupffer cell and interleukin-12-dependent loss of natural killer T cells in hepatosteatosis.

Authors:  Michael Kremer; Emmanuel Thomas; Richard J Milton; Ashley W Perry; Nico van Rooijen; Michael D Wheeler; Steven Zacks; Michael Fried; Richard A Rippe; Ian N Hines
Journal:  Hepatology       Date:  2010-01       Impact factor: 17.425

View more
  203 in total

1.  Inhibition of hedgehog signaling ameliorates hepatic inflammation in mice with nonalcoholic fatty liver disease.

Authors:  Hyunjoo Kwon; Kyoungsub Song; Chang Han; Weina Chen; Ying Wang; Srikanta Dash; Kyu Lim; Tong Wu
Journal:  Hepatology       Date:  2015-12-18       Impact factor: 17.425

Review 2.  Targeting Cell Death and Sterile Inflammation Loop for the Treatment of Nonalcoholic Steatohepatitis.

Authors:  Alexander Wree; Wajahat Z Mehal; Ariel E Feldstein
Journal:  Semin Liver Dis       Date:  2016-02-12       Impact factor: 6.115

Review 3.  Non-coding RNAs in hepatocellular carcinoma: molecular functions and pathological implications.

Authors:  Chun-Ming Wong; Felice Ho-Ching Tsang; Irene Oi-Lin Ng
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2018-01-10       Impact factor: 46.802

4.  The utility of noninvasive scores in assessing the prevalence of nonalcoholic fatty liver disease and advanced fibrosis in type 1 diabetic patients.

Authors:  Amandeep Singh; Phuc Le; Rocio Lopez; Naim Alkhouri
Journal:  Hepatol Int       Date:  2018-01-09       Impact factor: 6.047

5.  Structural and practical identifiability of dual-input kinetic modeling in dynamic PET of liver inflammation.

Authors:  Yang Zuo; Souvik Sarkar; Michael T Corwin; Kristin Olson; Ramsey D Badawi; Guobao Wang
Journal:  Phys Med Biol       Date:  2019-09-05       Impact factor: 3.609

6.  Association between PNPLA3 (rs738409), LYPLAL1 (rs12137855), PPP1R3B (rs4240624), GCKR (rs780094), and elevated transaminase levels in overweight/obese Mexican adults.

Authors:  Yvonne N Flores; Rafael Velázquez-Cruz; Paula Ramírez; Manuel Bañuelos; Zuo-Feng Zhang; Hal F Yee; Shen-Chih Chang; Samuel Canizales-Quinteros; Manuel Quiterio; Guillermo Cabrera-Alvarez; Nelly Patiño; Jorge Salmerón
Journal:  Mol Biol Rep       Date:  2016-10-17       Impact factor: 2.316

7.  Increased circulating zonulin in children with biopsy-proven nonalcoholic fatty liver disease.

Authors:  Lucia Pacifico; Enea Bonci; Lidia Marandola; Sara Romaggioli; Stefano Bascetta; Claudio Chiesa
Journal:  World J Gastroenterol       Date:  2014-12-07       Impact factor: 5.742

8.  Hybrid inhibitor of peripheral cannabinoid-1 receptors and inducible nitric oxide synthase mitigates liver fibrosis.

Authors:  Resat Cinar; Malliga R Iyer; Ziyi Liu; Zongxian Cao; Tony Jourdan; Katalin Erdelyi; Grzegorz Godlewski; Gergő Szanda; Jie Liu; Joshua K Park; Bani Mukhopadhyay; Avi Z Rosenberg; Jeih-San Liow; Robin G Lorenz; Pal Pacher; Robert B Innis; George Kunos
Journal:  JCI Insight       Date:  2016-07-21

9.  NLRP3 inflammasome driven liver injury and fibrosis: Roles of IL-17 and TNF in mice.

Authors:  Alexander Wree; Matthew D McGeough; Maria Eugenia Inzaugarat; Akiko Eguchi; Susanne Schuster; Casey D Johnson; Carla A Peña; Lukas J Geisler; Bettina G Papouchado; Hal M Hoffman; Ariel E Feldstein
Journal:  Hepatology       Date:  2017-12-28       Impact factor: 17.425

Review 10.  Insulin resistance in development and progression of nonalcoholic fatty liver disease.

Authors:  Shahinul Alam; Golam Mustafa; Mahabubul Alam; Nooruddin Ahmad
Journal:  World J Gastrointest Pathophysiol       Date:  2016-05-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.